From Oxbryta’s suspension to Casgevy and Lyfgenia’s approval, sickle-cell disease stands between caution and hope.
Related Posts
Looking for help with today’s New York Times Wordle? Here are some expert hints, clues and commentary to help you…
Our willingness to engage with one another amid AI is the ultimate proof of humane hybrid humanity. The delusion of…
NetApp sues former CTO who allegedly built competing startup “Red Stapler” while still employed, then sold it to rival VAST…
Looking for help with today’s New York Times Pips? We’ll walk you through today’s puzzle and help you match dominoes…
Simon Lockerby, founder and co-CEO of Fateless, a British video game developer, discusses the making of his first game, Godforge.
Relationship experts have turned something as seemingly unpredictable as marriage into an exact science. Here’s what decades of research reveals…
AI-driven autonomy is transforming transportation, reshaping vehicles, infrastructure, manufacturing, sustainability, and national competitiveness worldwide, rapidly.
The new Samsung Black Friday Price Promise looks good, but the fine print says otherwise. Here’s what you need to…
The AI bubble doesn’t reflect reality. This article reveals how energy, economics, and new infrastructure, not hype, are reshaping the…
Looking for some good movies to watch this week? Here are 10 great options new to streaming on Netflix and…